Mean ± SEM maximum change in intraocular pressure (IOP) data for the treated eye and the analysis of variance P values for drug effects and the comparison of the vehicle treatment with each group receiving a topical ophthalmic diclofenac sodium formulation containing a proprietary polymeric drug delivery system(ISV-205). There was a significant difference among groups by the analysis of variance (P = .05). The asterisk indicates P = .02, ie, a significantly lower pressure existed in the 0.06% ISV-205 group, specifically compared with vehicle.
Mean change in intraocular pressure(IOP) by time receiving prednisolone acetate and vehicle or a topical ophthalmic diclofenac sodium formulation containing a proprietary polymeric drug delivery system (ISV-205). A smaller mean increase in IOP was noted between the vehicle and the 0.06% ISV-205 group after 3 (P = .03) and 5 (P = .01) weeks of treatment.
Stewart WC, for the ISV-205 Study Group. Prevention of Corticosteroid-Induced Intraocular Pressure Elevation Using ISV-205. Arch Ophthalmol. 2003;121(11):1543-1547. doi:10.1001/archopht.121.11.1543
To determine whether a topical ophthalmic diclofenac sodium formulation containing a proprietary polymeric drug delivery system (ISV-205), when dosed concomitantly with 1% prednisolone acetate, is effective in blocking the intraocular pressure (IOP) response in humans.
This was a multicenter, prospective, double-masked, parallel, vehicle-controlled study. We included 136 first-degree relatives of subjects with primary open-angle glaucoma. Subjects were randomized to receive 0.06% or 0.1% ISV-205 or vehicle while concomitantly receiving 1% prednisolone for 6 weeks.
During the treatment period, the mean ± SD maximum IOP increase(7.3 ± 6.5 mmHg for vehicle, 4.9 ± 4.6 mmHg for 0.06% ISV-205, and 5.9 ± 4.9 mmHg for 0.1% ISV-205) was significantly less with the 0.06% formulation than with placebo (P = .02). The overall mean change in IOP was 3.6, 2.0, and 2.4 mmHg in the vehicle, 0.06% ISV-205, and 0.1% ISV-205 groups, respectively, which was significant between the 0.06% ISV-205 and vehicle groups (P = .05). Eight(17%) of the 46 subjects receiving vehicle terminated the study because of high IOPs, compared with 1 (2%) of the 45 subjects receiving 0.06% ISV-205 and 3 (7%) of the 45 subjects receiving 0.1% ISV-205 (P = .03). The number of subjects with a clinically important corticosteroid response (≥10–mm Hg increase) was greater in the vehicle group (12[28%] of 43 subjects) compared with the 0.06% ISV-205 group (3 [7%] of 42 subjects) (P = .01). Adverse events were similar between treatments.
This study suggests that ISV-205 limits the corticosteroid-induced elevated IOP in first-degree relatives of subjects with glaucoma. Future studies are needed to confirm these results and explore the possible role of this drug in treating glaucoma.
OPHTHALMIC corticosteroids were first reported to cause intraocular pressure (IOP) elevation in the 1950s. Subsequent studies showed that corticosteroid-induced IOP elevation is relatively common, 1,2 the magnitude of corticosteroid-induced IOP elevation varies markedly from one person to the next, 3 and the extent of elevated IOP depends on the frequency and duration of the topical administration.4
Treatment exists to control corticosteroid-induced IOP elevation (eg, latanoprost and β-blockers). Ocular hypotensive agents, however, generally may be associated with ocular or systemic adverse effects that make them unacceptable to some subjects.5 In addition, a risk of glaucomatous damage may exist, from the corticosteroid response, before the discovery and treatment of the elevated IOP.
To address this problem, one company (In Site Vision Incorporated, Alameda, Calif) is investigating a prophylactic treatment approach using a topical ophthalmic diclofenac sodium formulation containing a proprietary polymeric drug delivery system (ISV-205) as a means to block corticosteroid-induced IOP elevation, rather than treat it once it has occurred. The proprietary polymeric drug delivery system (Dura Site) is used to enhance drug delivery and penetration.
In this study, we evaluated the ability of 0.06% or 0.1% ISV-205 (In Site Vision Incorporated), compared with vehicle, to block the IOP increase from concomitantly administered 1% prednisolone acetate in first-degree relatives of subjects with glaucoma.
This double-masked, vehicle-controlled, clinical trial was performed at 5 investigational sites. One hundred thirty-six healthy volunteers, who were first-degree offspring or siblings of subjects with primary open-angle glaucoma, participated in the study. These subjects were randomly assigned to receive 1 of 2 concentrations (0.06% or 0.1%) of ISV-205 or vehicle instilled 3 times daily for 6 weeks while concomitantly receiving prednisolone 4 times daily.
The following were the inclusion criteria for this study: aged at least 18 years; had signed and dated an institutional review board–approved informed consent form; was likely to complete the study and comply with appropriate instructions; was a first-degree relative of a subject with primary open-angle glaucoma; was a healthy volunteer with IOPs of 21 mmHg or lower in both eyes; had a corrected log MAR visual acuity of 0.6 (20/80) or better in each eye; and if of childbearing potential, then was practicing a medically acceptable form of birth control and demonstrated a negative result on a pregnancy test before enrolling into the study.
Subjects were excluded from this study if they had an uncontrolled systemic disease (cardiovascular disease, hypertension, or diabetes mellitus); had an unstable or an alteration of existing long-term systemic therapy that could influence the IOP (ie, systemic hypertension medicines); used any other ocular medication apart from artificial tears; used any other corticosteroid within 30 days before the screening/baseline vist (visit 1); had glaucoma or ocular hypertension (IOPs >21 mmHg) in either eye; were pregnant or nursing; had a known hypersensitivity to any of the ingredients in the study medication or to other nonsteroidal anti-inflammatory agents; demonstrated bleeding tendencies; had corneal or eyelid abnormalities that would preclude accurate applanation tonometry; underwent ocular surgery in either eye within the past 6 months or laser surgery within the past 3 months; required contact lens wear in the treated eye during the study; had a current external eye disease, inflammation, or an eye infection; had posterior subcapsular cataracts in either eye; participated in previous ISV-205 studies; participated in any research study within the 30 days before this study; or were concurrently participating in any other research study.
Each subject randomly received either 1 of 2 concentrations of ISV-205(0.06% or 0.1%) or vehicle. All study medications were administered as topical eyedrops to one randomly selected eye (treated eye). The ISV-205 and vehicle were packaged in identical single-dose unit containers. Neither the investigators and their staff nor the subjects were told which drug the subject received.
At the screening/baseline visit (visit 1), the study drug (0.06% ISV-205, 0.1% ISV-205, or vehicle) was administered by a clinical study coordinator 3 times at approximately 4-hour intervals. A comfort query was performed after each of the 3 doses.
Subjects were examined again after a minimum of a 1-week washout (visit 2), and began the 6-week dosing period (weekly visits 3-8). During active treatment (visits 3-8), the study drug was administered 3 times a day (6-8 am, 11 am-1 pm, and 9-11 pm), and prednisolone acetate (Pred Forte; Allergan, Inc, Irvine, Calif) was administered 4 times a day (5-10 minutes before the administration of the study drug and at 1 additional afternoon dosage [4 or 6 pm]). At visit 8, the study medication and prednisolone were discontinued. Each subject was examined again (visit 9) after a 1-week medicine-free period.
At each visit, subjects underwent the following: Goldmann applanation tonometry between 7 and 10 am, slitlamp biomicroscopy, and the determination of Early Treatment Diabetic Retinopathy Study visual acuity. At visits 1 and 9, automated double-threshold perimetry (Humphrey Field Analyzer; Humphrey Instruments, San Leandro, Calif) and dilated ophthalmoscopy also were performed.
The maximum change in IOP during the 6 weeks of using prednisolone and study drug was the primary efficacy variable. The significance level for all statistical tests was set at .05 and was 2-tailed. Differences among the treatments were evaluated with an analysis of variance as an intent-to-treat analysis.6
Secondary efficacy end points that were evaluated by repeated analysis of variance measures included the overall mean change in IOP during the 6 weeks of treatment and the mean change in IOP at each visit.6 Also, subjects were categorized as corticosteroid responders based on the definition of a clinically significant change (≥10 mmHg from baseline at visit 1).7 The responder rates and differences in the termination rate from the study were evaluated by a χ2 test.6
Safety was evaluated by the occurrence of adverse experiences and by changes from baseline in visual acuity, biomicroscopy, ophthalmoscopy, and visual fields. Differences in the reason for study exit also were evaluated by a χ2 test.6 Comfort ratings and the incidence, severity, and duration of symptoms were evaluated by a χ2 test.6 Subject characteristics were evaluated by either an analysis of variance or a χ2 test.6
One hundred thirty-six subjects were randomly assigned to 1 of the 3 treatment groups. Table 1 shows the disposition of these subjects summarized by treatment group. One hundred nine (80.1%) of the enrolled subjects completed the study.
Table 2 summarizes the demographic characteristics by treatment group for the 136 subjects who enrolled into the study. There were no statistically significant differences among the 3 treatment groups for age, sex, race, or iris color.
The ISV-205 study medicine limited the increase in IOP induced by prednisolone, as evidenced by the following. First, a significantly smaller mean maximum increase in IOP occurred during the 6 weeks of dosing among the 3 treatment groups, with the 0.06% ISV-205 group having the least elevation in pressure(mean ± SD: 4.9 ± 4.6, 5.9 ± 4.9, and 7.3 ± 6.5mmHg in the 0.06% ISV-205, 0.1% ISV-205, and vehicle groups, respectively; P = .05). In addition, a significantly lower pressure existed in the 0.06% ISV-205 group, specifically compared with vehicle (P = .02) (Figure 1). Second, a smaller mean increase in IOP was noted between the vehicle and the 0.06% ISV-205 groups after 3 (visit 5, P = .03) and 5 (visit 7, P = .01) weeks of treatment (Figure 2). Third, the overall mean ± SD change in pressure was significantly lower (P = .05) in the 0.06% ISV-205 group than in the vehicle group during the 6 weeks with 0.06% ISV-205 (2.0± 4.2 mmHg) and 0.1% ISV-205 (2.4 ± 4.8 mmHg) treatment compared with vehicle (3.6 ± 6.6 mmHg). Fourth, 8 (17%) of the 46 subjects in the vehicle group were terminated from the study because of high IOPs compared with 1 (2%) of the 45 subjects in the 0.06% ISV-205 group and 3 (7%) of the 45 subjects in the 0.1% ISV-205 group (P = .03). Finally, significantly (P = .01) more subjects were corticosteroid responders (≥10 mmHg increase) in the vehicle group (12[28%] of 43 subjects) than in the 0.06% ISV-205 group (3 [7%] of 42 subjects). Furthermore, a significant difference was observed between vehicle and 0.06% ISV-205 when subjects were grouped by different levels of pressure elevation(P = .03) (Table 3).
No significant differences were observed in the incidence of any individual adverse event or clinical measure among groups. A trend to increased stinging/burning was noted, however, by unsolicited reports (Table 4) and subject ratings of comfort (P =.09). The stinging/burning was most frequently rated as mild in severity and lasted less than 1 minute.
The number of subjects terminating the study because of adverse effects was similar among the 3 treatment groups: 1 subject (2%) taking vehicle, 1(2%) taking 0.06% ISV-205, and 0 taking 0.1% ISV-205. Two serious adverse events were reported during the study. One subject using vehicle had a myocardial infarction, and one using 0.1% ISV-205 had serious injuries resulting from a motorcycle crash. Neither event was believed related to the study drug.
The mechanism by which corticosteroids increase IOP is a topic of investigation. In studies using a human trabecular meshwork cell culture system, researchers8- 10 reported that 1 to 3 weeks of treatment with the corticosteroid dexamethasone caused a progressive induction of the trabecular meshwork–inducible glucocorticoid response(TIGR) protein/myocilin (MYOC) protein in human trabecular meshwork cells. The time course of the protein induction and the dose-response curve paralleled those of IOP elevation caused by corticosteroids in humans.3,4,9,10 These studies led to the cloning of the major corticosteroid-induced species, which has become known as the TIGR/MYOC gene for adult and juvenile open-angle glaucoma.11
Researchers8- 10 later determined that the diclofenac dose dependently inhibited the induction of TIGR/MYOC protein in human trabecular meshwork cells treated with dexamethasone for 1 to 3 weeks. Subsequently, ISV-205 was developed. This preparation was designed to prolong the corneal contact of diclofenac to provide sufficient aqueous levels, which may not be available from the commercial preparation, to block TIGR/MYOC gene induction. Commercial diclofenac sodium (Voltaren; Novartis, Atlanta, Ga) is indicated for the treatment of inflammation following cataract extraction and for discomfort following corneal refractive surgery.
In this study, we evaluated if 0.1% and 0.06% ISV-205 could block the corticosteroid-induced IOP elevation in first-degree relatives of subjects with primary open-angle glaucoma. Such individuals have had a 70% chance of showing an exaggerated IOP elevation when given corticosteroids for 6 weeks.12,13 The 1% prednisolone formulation was chosen to induce the IOP increase in this study because it is one of the strongest ocular corticosteroids commercially available.14
This study showed that ISV-205 limited the IOP elevation associated with prednisolone treatment, as demonstrated by the following. First, there was a significantly lower maximum increase in pressure in the 0.06% ISV-205 group compared with the vehicle group. Second, there were consistently smaller increases at individual visits compared with the vehicle group. These 2 differences were significant for the 0.06% ISV-205 group at visits 5 and 7. Third, the overall mean change in pressure was significantly lower in the 0.06% ISV-205 group, and a trend existed in the 0.1% ISV-205 group, compared with vehicle. Fourth, fewer subjects left the study because of a high IOP in the ISV-205 groups compared with the vehicle group. Last, there were fewer subjects in the 0.06% ISV-205 group who were corticosteroid responders (≥10–mm Hg increase in pressure) than in the vehicle group.
The reason why the IOP elevation was blunted is not known exactly, but it presumably was due to diclofenac in the ISV-205 formulation blocking the induction of the TIGR/MYOC protein generated from the trabecular meshwork cells. By preventing this induction and subsequent deposition in the meshwork, diclofenac may work to maintain outflow facility. However, any prevention of reduced outflow from diclofenac has not been shown directly in human studies or in vitro. In addition, the exact mechanism of diclofenac in these subjects remains unknown.
In this study, the 0.06% concentration was apparently more effective than the 0.1% concentration in preventing the IOP elevation. The reason for this finding was not determined exactly, and should be explained by future studies. Perhaps there was an inconsistent response to the corticosteroid or a variable compliance among subjects that could explain this unexpected finding.
The ISV-205 was safe and tolerable in this study. However, there was a trend with both formulations for mild burning/stinging of a short duration following instillation of the medicine compared with the vehicle.
The results of this study are important for several reasons. First, they may point to a new treatment for subjects who are receiving corticosteroids for uveitis, inflammation, or postsurgical complications to help prevent a concomitant IOP elevation. Such a concomitant treatment would have the advantage of preventing an elevated pressure and possible glaucomatous damage. Second, and perhaps most important, because the TIGR protein is more frequent in subjects with glaucoma, ISV-205 might lead to treatments that help prevent or treat this disease as well.8
This study suggests that ISV-205 limits a corticosteroid-induced IOP increase in first-degree relatives of subjects with glaucoma.
This study did not evaluate the effect of ISV-205 long term in treating the subjects who have used topical corticosteroids long term. In addition, this study did not evaluate the effect of ISV-205 in subjects with primary open-angle glaucoma or in preventing pressure elevations in subjects predisposed to high IOPs. Future research hopefully will clarify the use, if any, of ISV-205 in clinical medicine.
Corresponding author: William C. Stewart, MD, Pharmaceutical Research Network, LLC, 1639 Tatum St, Charleston, SC 29412-2464 (e-mail: email@example.com).
Submitted for publication July 22, 2002; final revision received May 15, 2003; accepted June 10, 2003.Article
Texan Eye Care, Austin: Thomas R. Walters, MD. Medical Center Ophthalmology, San Antonio, Tex: Richard M. Evans, MD. Atlanta Research Company, LLC, Atlanta, Ga: Douglas Day, MD. Scripps Clinic, La Jolla, Calif: Mitchell H. Friedlaender, MD. Pharmaceutical Research Network, LLC, Charlston, SC: William C. Stewart, MD. In Site Vision Incorporated, Alameda, Calif: Cheryl Chen, BS, MBA; Erwin Si, PhD.